AstraZeneca Financials

Market Capitalization £161.61 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	28.13
Forward PE	14.18
Price to Sales TTM	£2.94
Price to Book MRQ	£386.68
Enterprise to Revenue	3.33
Enterprise to EBITDA	10.03

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	14.14%
Operating Margin	27.94%
Return on Assets TTM	8.16%
Return on Equity TTM	19.79%

Income Statement

Revenue TTM	£40,271,015,998
Revenue per Share TTM	£35.47
Quarterly Revenue Growth	7.20%
Gross Profit TTM	£33,200,771,134
EBITDA	£16,065,000,000
Net Income to Common TTM	£5,692,523,789
Diluted EPS TTM	£3.64
Quarterly Earnings Growth YoY	33.80%

Balance Sheet

Total Cash MRQ	£3,951,513,605
Total Cash per Share MRQ	£3.48
Total Debt MRQ	£
Total Debt to Equity MRQ	77.11
Current Ratio MRQ	0.90
Book Value per Share MRQ	£26.48

Cash Flow

Operating Cash Flow TTM	£9,586,174,589
Levered Free Cash Flow TTM	£6,845,658,559

AZN Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	1,550,103,897
Float Shares	1,543,211,000
Avg 10 Volume	2,092,965
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	0.04%
% Held by Institutions	53.53%

Stock Price Summary

Beta	0.17
Fifty Two Week Low	£9573.51
Fifty Two Week High	£13388.00
Fifty Two Week Change	-16.26%
Day 50 MA	£10503.00
Day 200 MA	£10923.48

Dividends and Splits

Forward Annual Dividend Rate	£336.00
Forward Annual Dividend Yield	3.24%
Trailing Annual Dividend Rate	£245.60
Trailing Annual Dividend Yield	2.37%
Payout Ratio	63.08%
Dividend Date
Ex Dividend Date	2025-02-20
Last Split Factor
Last Split Date